logo linkedin

Com­pounds interaction

Inves­ti­ga­tion of the puta­tive inter­ac­tion between two drugs on sev­eral mod­els at ther­a­peu­tic con­cen­tra­tions and their con­se­quences on the action poten­tial prolongation

Study of the addi­tive effects of 2 drugs on car­diac function:

  • on hERG channel
  • on action potentials
  • on iso­lated Lan­gen­dorff per­fused heart


ex : Ziprazi­done & Sotalol

Indeed, Phys­ioS­tim focused on ziprasi­done, an atyp­i­cal antipsy­chotic devoided of car­diac adverse effects in spite of its propen­sity to pro­long the QT-​interval via a hERG inhi­bi­tion. More­over, very lit­tle infor­ma­tion is avail­able con­cern­ing phar­ma­co­dy­namic inter­ac­tions between ziprasi­done and other hERG chan­nel block­ers. Thus, we inves­ti­gated the puta­tive inter­ac­tion between ziprasi­done and d,l-sotalol on the hERG chan­nels at ther­a­peu­tic con­cen­tra­tions and their con­se­quences on the action poten­tial prolongation.




Effects of ziprasi­done 10 µmol/​L super­fused alone (panel A) or in asso­ci­a­tion with d,l-sotalol 10 µmol/​L (panel B) on hERG chan­nel inhi­bi­tion.
Zip: ziprasi­done; sot: d,l-sotalol. Cur­rents were recorded at room tem­per­a­ture. Pulses cycling rate was 30s.

figure compound interaction